News Releases Year: All News201920182017201620152014 Items per page All News2550 Summary ToggleContraVir Pharmaceuticals to Present at Virtual Investor Conference Summary Toggle July 5, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces $10.8 Million in Expected Gross Proceeds from Recently Expired Rights Offering Summary Toggle June 29, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Initiates Dosing of CRV431 in First In-Human Trial Summary Toggle June 25, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL™ Summary Toggle June 21, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Summary Toggle June 20, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals to Provide Corporate, Business and Clinical Updates Summary Toggle June 18, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States Summary Toggle June 14, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record Summary Toggle June 12, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering Summary Toggle June 5, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Liver Fibrosis in a Preclinical Model Summary Toggle May 31, 2018 View News Release > Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
